KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Inventory (2020 - 2026)

Teladoc Health's Inventory history spans 7 years, with the latest figure at $31.6 million for Q1 2026.

  • On a quarterly basis, Inventory fell 16.98% to $31.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $31.6 million, a 16.98% decrease, with the full-year FY2025 number at $38.2 million, changed 0.17% from a year prior.
  • Inventory hit $31.6 million in Q1 2026 for Teladoc Health, down from $38.2 million in the prior quarter.
  • Over the last five years, Inventory for TDOC hit a ceiling of $70.7 million in Q1 2022 and a floor of $29.5 million in Q4 2023.
  • Historically, Inventory has averaged $42.4 million across 5 years, with a median of $38.1 million in 2024.
  • Biggest five-year swings in Inventory: plummeted 47.62% in 2023 and later rose 29.22% in 2024.
  • Tracing TDOC's Inventory over 5 years: stood at $56.3 million in 2022, then plummeted by 47.62% to $29.5 million in 2023, then increased by 29.22% to $38.1 million in 2024, then rose by 0.17% to $38.2 million in 2025, then dropped by 17.4% to $31.6 million in 2026.
  • Business Quant data shows Inventory for TDOC at $31.6 million in Q1 2026, $38.2 million in Q4 2025, and $39.9 million in Q3 2025.